United Therapeutics Earnings: Here’s Why Investors are Selling Shares Now

  Google+ | + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

United Therapeutics Corp. (NASDAQ:UTHR) delivered a profit and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 4.97%.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

United Therapeutics Corp. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased 7.75% to $1.19 in the quarter versus EPS of $1.29 in the year-earlier quarter.

Revenue: Rose 20.04% to $245.14 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: United Therapeutics Corp. reported adjusted EPS income of $1.19 per share. By that measure, the company missed the mean analyst estimate of $1.47. It beat the average revenue estimate of $241.14 million.

Quoting Management: “I am pleased that our first quarter 2013 results were solid, providing a strong foundation for continued growth,” said Martine Rothblatt, Ph.D., United Therapeutics’ Chairman and Chief Executive Officer. “Our pipeline continues to grow, with two phase 3 trials, a new phase 1 trial of mesenchymal stem cells in PAH patients and advances in our strategic product portfolio.”

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business